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Cyclodextrins are popular drug solubilizers, but the use of the natural cyclodextrins is hampered by 
their tendency to co-precipitate with the drug. To understand and overcome such problems, we have 
studied the solubility of dexamethasone in the presence of natural β-cyclodextrin and γ-
cyclodextrin, individually and in various combinations. Equilibrium models of the phase-solubility 
diagrams with individual cyclodextrins revealed that dexamethasone was solubilized as 1:1 
complexes, but formation of insoluble higher-order complexes set an upper limit to the 
concentration of solubilized dexamethasone. This limit could be raised from 8 mM to 17 mM by 
using combinations of the two cyclodextrins, as their solubilizing properties were additive in some 
regions of the phase-solubility diagram and synergistic in other regions. The additive effects arise 
from the additivity of solubilities – same phenomenon contributes to the good solubilizing 
properties of many modified cyclodextrins. The synergistic effects, however, could not be 
explained. The results open up for an increased use of the natural cyclodextrins as an improved 
alternative to modified cyclodextrins. 
 






Cyclodextrins (CDs) are often used drug solubilizers due to their ability to form water-soluble 
inclusion complexes with a large variety of drug molecules.1 The cyclic structure of CDs consists of 
typically 6, 7, or 8 linked glucose monomers, termed α, β, and γCD, respectively. Depending on the 
diameter, CDs may encapsulate drug moieties of various sizes. In addition to these so-called natural 
CDs, a large number of chemically modified CDs have been synthesized, the most common being 
hydroxypropylated, sulfobutylated, and methylated CDs. These modified CDs have a higher 
aqueous solubility and an often improved toxicological profile compared to their parent CDs.2 In 
contrast to the natural CDs, they are highly heterogeneous samples, containing a variety of CDs 
differing in the degree and pattern of substitution. 
The drug-solubilizing properties of a given CD is often studied by phase-solubility (PS) analysis in 
which the concentration of dissolved drug is plotted against the amount of added CD.3,4 There 
seems to be a general tendency for modified CDs to result in A-type PS profiles in which the 
concentration of dissolved drug increases monotonously with the amount of added CD. In contrast, 
the natural β and γCD often exhibit B-type profiles in which the formed complexes have a limited 
solubility and precipitate from the solution.4 Such behavior is problematic and may limit the use of 
natural β and γCD. On the other hand, the natural CDs often have higher binding constants, 
meaning that less CD is required to solubilize a given amount of drug. This may be of importance in 
solid oral dosage forms where the bulk formulation preferably should be contained in a single tablet 
of limited size.5 Further, the complex sample composition of the modified CDs may be a drawback 
in terms of sample characterization, batch-to-batch variations and related regulatory issues. In order 
to improve the use of the natural CDs, it is desirable to understand why they, in contrast to the 




It has previously been discovered that addition of small amounts of HPγCD to natural γCD 
significantly improves the complexation efficiency of the latter.6 This synergistic effect was 
speculated to be related to the formation of aggregates of CDs and their complexes,7 but this 
hypothesis is difficult to prove due to the presumably short-lived and complex nature of the 
aggregates. The present work aims to shed light on the causes for the reported synergistic effects 
and to understand why the solubilizing properties of natural and modified CDs are so different. To 
keep things simple, the complex mixtures of modified CDs were avoided, and the solubilizing 
properties of two pure CDs, βCD and γCD, were studied individually and in various mixing ratios. 
Dexamethasone (DX) was chosen as drug molecule as the reported synergistic effects were 
observed for this particular drug. Like most other steroids, DX is known to give BS-type PS profiles 
with natural β and γCD and AL-type profiles with modified CDs.8–13 Further, the molecular 
mechanisms behind the PS diagram of γCD with the structurally similar steroid hydrocortisone 
were recently described in detail.14 It seems feasible to obtain a similar mechanistic understanding 
of the current system consisting of one drug and two CDs. Such understanding may be extended to 
complex mixtures of CDs, like the modified CDs, and may explain the reported synergistic effects. 
Ultimately, we hope this study can contribute to overcoming the problems associated with the low 




PS diagrams are constructed by measuring the total solubility of a fixed amount of solid substrate 
(S, in this work DX) in a medium containing increasing amounts of solubilizer or ligand (L, in this 
work CD). The theoretical framework for the various types of PS diagrams were laid out by 
Higuchi and Connors in 19653 and later developed for several special cases of BS -type PS 
diagrams.14–16 The interested reader is referred to these references for details; the present text only 
highlights the main points. 
BS-type PS profiles occur when one of the formed complexes has a limited solubility and 
precipitates from the solution. In the present case, DX forms soluble 1:1 complexes and insoluble 
higher-order complexes with both CDs. As shown in Figure 2, this gives rise to three regions in the 
PS diagram. In region I, the DX concentration in the liquid phase increases linearly with increasing 
amounts of CD. In region II, all concentrations are constant as the precipitate consists of two solid 
phases of respectively precipitated higher-order complex and solid DX. This maintains constant 
concentrations of all dissolved species. Region III occurs when enough CD has been added such 
that all solid DX is solubilized or has precipitated as higher-order complexes. The absence of solid 
DX permits the concentration of free DX to go below its intrinsic solubility, S0, and continued 
addition of CD will gradually deplete DX from the solution and precipitate it as higher-order 
complex. 
The mathematical modelling rests on a set of equations based on mass conservation and chemical 
equilibria. The relevant mass conservations relates to the total concentrations of DX (Seq) and CD 
(Leq) in solution: 
𝑆𝑆𝑒𝑒𝑒𝑒 = [𝑆𝑆] + [𝐿𝐿𝑆𝑆]    (1) 
𝐿𝐿𝑒𝑒𝑒𝑒 = [𝐿𝐿] + [𝐿𝐿𝑆𝑆]    (2) 
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and to the distribution of molecules between solution and precipitate: 
𝑆𝑆𝑡𝑡 = 𝑆𝑆𝑒𝑒𝑒𝑒 + 𝑦𝑦 × 𝐿𝐿𝑥𝑥𝑆𝑆𝑦𝑦
𝑝𝑝𝑝𝑝𝑒𝑒𝑝𝑝    (4) 
𝐿𝐿𝑡𝑡 = 𝐿𝐿𝑒𝑒𝑒𝑒 + 𝑥𝑥 × 𝐿𝐿𝑥𝑥𝑆𝑆𝑦𝑦
𝑝𝑝𝑝𝑝𝑒𝑒𝑝𝑝     (5) 
St and Lt are the total amounts of DX and CD added to the vial, and LxSyprec is the amount of higher-
order complexes in the precipitate. 
The concentration of 1:1 complexes, [LS], is governed by the binding constant: 
[𝐿𝐿𝑆𝑆] = 𝐾𝐾 × [𝐿𝐿] × [𝑆𝑆]    (6) 
and the precipitation of higher-order complexes is determined by the solubility product: 
𝐾𝐾𝑆𝑆
𝑥𝑥𝑦𝑦 = [𝐿𝐿]𝑥𝑥[𝑆𝑆]𝑦𝑦    (7) 
Solving this system of equations with the region-specific constraints yields the concentrations of the 
dissolved species, as shown in the Supporting Information. It is important to note that the model 
assumes that no higher-order complexes (x > 1 and/or y > 1) are present in the liquid phase. Such 
complexes may only be present in the solid phase. For this reason, no concentrations of higher-
order complexes appear in the equations and no equilibrium constant for the formation of higher-
order complexes in the liquid phase is defined. These are omitted from the model as the presently 
studied systems turned out to behave similarly to a previous study of hydrocortisone and γCD in 






β-cyclodextrin (purity ≥ 97%) and γ-cyclodextrin (purity ≥ 98%) were purchased form Sigma-
Aldrich. The water content of the cyclodextrins (11.26 ± 0.08wt% for βCD, 9.07 ± 0.05wt% for 
γCD) was determined from the mass loss upon drying. Dexamethasone (96% purity) was from 
Acros Organics. Milli-Q water was used for all solutions. 
 
Isothermal titration calorimetry 
To determine the binding constants of DX to each the two CDs calorimetric titrations were made on 
a VP-ITC (Malvern Panalytical, Malvern, UK) with a 1.4257 ml reaction cell. 3 mM aqueous 
solutions of CD were titrated into 0.15 mM aqueous solutions of DX at 10, 25, 40, and 55 °C at a 
stirring speed of 310 rpm. Each titration consisted of 29 injections, each injection having a volume 
of 10μL. The resulting enthalpograms were analyzed by a global fitting procedure using in-house 
Matlab scripts to yield the binding constant, stoichiometry, binding enthalpy, and change in heat 
capacity.17 
 
Experimental generation of phase-solubility diagrams 
For each phase-solubility diagram, a constant amount of solid DX was weighed and transferred to 2 
ml Eppendorf tubes. 14.3 mg (35 mM) DX was used for the PS diagrams with individual CDs and 
16.4 mg (40 mM) for the experiments with mixtures of CDs. Varied amounts of CD(s) and 1 ml of 
Milli-Q water was added to each tube. The tubes were agitated for at least 6 days at 400 rpm on a 
shaking table thermostatted at 25 °C. After equilibration, the solid particles were spinned down and 
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the supernatant was removed using a plastic Pasteur pipette. After filtering and appropriate dilution, 
the concentration of DX in the supernatant was measured using an Agilent 1100 Series HPLC. CD 
and DX were separated on a C18 column using 70% methanol/water as mobile phase, having a flow 
of 0.8 ml/min. 20 μl of each sample was injected once with a run time of 8 min. DX was eluted after 
5.9 min and its concentration was quantified from the absorbance at 250 nm.  
The tubes with the precipitate were dried overnight in vacuum at 55 °C and weighed to determine 
the contents of DX and CD. The amount of DX in the precipitate could be determined as the 
difference between added DX and DX in the supernatant. The remaining mass of the precipitate 
would then be CD. Then the amount of CD in the supernatant could be determined as the difference 
between added CD and CD in the precipitate. The errors resulting from this indirect determination 
of the CD concentrations were estimated from a similar treatment of the samples that only 
contained DX and water. These indicated that the CD concentrations could be determined with an 
error of less than 1 mM. 
 
Differential scanning calorimetry 
For each analyzed sample, 2-4 mg of dried precipitate was heated from 50 to 270 °C in aluminium 





Prior to exploring the solubilizing properties of mixtures of β and γCD, the solubilizing properties 
of individual CDs were characterized by PS analysis. Mathematical modelling of the PS diagrams 
confirmed a mechanistic model in which the CDs formed soluble 1:1 complexes and insoluble 
higher-order complexes. To verify the mathematical model, some of the parameters were 
determined by independent experiments. The 1:1 binding constants, K, were determined by 
isothermal titration calorimetry, and the intrinsic solubility of DX, S0, was determined by solubility 
measurements. 
 
Isothermal titration calorimetry 
Binding constants for the 1:1 complexes of DX with γCD and βCD were accurately determined by 
ITC. In principle, a single titration provides the binding constant, K, the binding enthalpy, ΔH, and 
the stoichiometry of the complex, N. A more robust method is to perform titrations at different 
temperatures and conduct a global fit of all titrations.17 This method employs an additional fitting 
parameter, the change in heat capacity (ΔCp), and ensures that the obtained results are consistent 
with fundamental thermodynamic relations. The results from the titrations of DX with γCD and 
βCD are shown in Figure 1. In both cases, the stoichiometry was very close to 1, indicating the 
formation of 1:1 complexes with both CDs. The binding constant for γCD (13.9 mM-1) was more 
than twice as high as for βCD (5.7 mM-1). The measured binding constant for the βCD:DX complex 
was similar to reported values measured under similar conditions (4.7 mM-1 10, 6.2 mM-1 18, 7.4 
mM-1 19). For the γCD:DX complex, the measured binding constant differed significantly from 
previously reported values determined by phase-solubility analysis (27 mM-1 10, 1.2 mM-1 6). The 
presently reported values are assumed to possess a higher accuracy due to the employed global 
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fitting procedure. The large number of data points and the low degree of correlation between the 
fitting parameters yields a precise estimate of the binding constant, as evidenced by the statistics in 
Figure 1. 
 
Figure 1 Enthalpograms from the titration of DX with γCD (A) and βCD (B) conducted at 10°C, 25°C, 40°C, and 55°C. The parameters 
obtained from the global fit to the experiments are listed in the tables along with their statistics. 
 
Dexamethasone solubilized by γ-cyclodextrin 
The PS diagram for DX solubilized by γCD was generated by adding a constant amount of solid 
DX, corresponding to 32.3 mM, to each vial and measuring the equilibrium concentration of DX in 
the aqueous phase. In the absence of γCD, the intrinsic solubility of DX was determined to 0.164 
mM ± 0.005 mM (±SD, n = 3). As the concentration of γCD in the added aqueous solvent 
increased, the amount of solubilized DX first increased linearly, then reached a plateau, followed by 
a sharp decrease. The resulting BS-type PS diagram is shown in Figure 2. From the length of region 
II the precipitation stoichiometry was determined to 1.48,3 thus indicating that γCD and DX 
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precipitated in a ratio of three γCDs to two DX molecules. It therefore seems appropriate to model 
the experimental data using a 3:2 model in which x and y in eq. 7 are 3 and 2, respectively. The 
black line in Figure 2 shows the prediction of the 3:2 model. Out of the three parameters that 
determines the shape of the model prediction, two of the parameters, K and S0, had already been 
determined by ITC and solubility measurements, respectively. The third parameter 𝐾𝐾𝑆𝑆32 was 
determined from the height of the plateau in region II (6.95 ± 0.09 mM) using eq. 8 (derived as eq. 





    (8) 
where 𝑆𝑆𝑒𝑒𝑒𝑒 is the height of the plateau. This yields 𝐾𝐾𝑆𝑆32 = 0.78 mM5. 
Figure 2 also shows the experimentally determined concentrations of CD in the liquid phase along 
with the prediction of the 3:2 model, using the same parameters as before. Due to the indirect 
determination of CD concentration from the mass of the precipitate these data points might be 
imprecise. It was not possible to determine the CD concentration directly by the UV-VIS detector in 
the HPLC system as the absorptivity of CDs is too low. It is possible, however, that direct 
determination of the CD concentrations by other detectors such as a charged aerosol detector20 
would have resulted in even better agreement between model and experiment. Nevertheless, the 
observed agreement clearly indicates that the model is plausible. This means that DX predominantly 
exists in solution as 1:1 complexes with γCD and precipitates in a 3:2 γCD:DX ratio at high 




Figure 2 Experimental phase-solubility diagram of DX solubilized by γCD (black squares, left axis) and total concentration of γCD in 
liquid phase (red squares, right axis). Solid lines are generated by the 3:2 model, using the following parameters: S0 = 0.164 mM, K = 
13.5 mM-1, and 𝐾𝐾𝑆𝑆32 = 0.78 mM5.  
 
Dexamethasone solubilized by β-cyclodextrin 
As for γCD, the solubilization of DX by βCD also resulted in a BS-type PS diagram (Figure 3) but 
with a second plateau which will be termed region IIA. In region II, the precipitate consists of two 
solid phases: pure DX and precipitated higher-order complex. In region IIA, the solubility of βCD 
was reached, and the precipitate consisted of a solid phase of pure βCD and another solid phase of 
precipitated higher-order complex. The length of the region II plateau indicated that βCD and DX 
precipitated in a ratio of 2:1 (CD to DX), and therefore the data were modeled by a 2:1 model in 
which DX is solubilized as 1:1 CD complexes and precipitated as 2:1 complexes. In addition to the 
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1:1 binding constant and the intrinsic solubility of DX, which were determined by ITC and 
solubility measurements, the model employs the 2:1 CD:DX solubility product, 𝐾𝐾𝑆𝑆21. Further, to 
describe region IIA, the intrinsic solubility of βCD, L0, was set to the previously reported value of 
16.3 mM at 25°C.21 
The value of 𝐾𝐾𝑆𝑆21 can be determined from the height of the region II plateau, as was done for γCD, 
but due to the more precise determination of the plateau in region IIA (4.42 ± 0.06 mM), this value 
was used to determine 𝐾𝐾𝑆𝑆21 according to eq. 8 (derived as eq. S10 in the SI) where L0 is the intrinsic 




     (9) 
yielding 𝐾𝐾𝑆𝑆21 = 12.6 mM3. The resulting plot of the 2:1 model generally revealed good agreement 
with the experimental data (Figure 3). In region I, however, there seemed to be a slight systematic 
deviation between the model and the experimental data. Linear regression to the data points in 
region I yielded a slope of 0.431, translating into a binding constant of 4.62 mM-1.3 This is a little 
lower than that determined by ITC but still within reasonable agreement, especially considering the 




Figure 3 Experimental phase-solubility diagram of DX solubilized by βCD (black squares, left axis) and total concentration of βCD in 
liquid phase (red squares, right axis). Solid lines are generated by the 2:1 model, using the following parameters: S0 = 0.164 mM, K = 
5.65 mM-1, 𝐾𝐾𝑆𝑆21 = 12.6 mM3, and L0 = 16.3 mM. 
 
Solubility of dexamethasone in mixtures of β-cyclodextrin and γ-cyclodextrin 
The above results convincingly show that the BS-type PS diagrams of DX with either βCD or γCD 
can be accounted for by equilibrium models where DX is solubilized by formation of 1:1 complexes 
with the CDs but precipitates in a 3:2 or 2:1 CD:DX ratio. Precipitation sets in once the 
concentrations of uncomplexed CD and DX exceed the solubility product of the precipitate. The 
thorough understanding of these individual systems should in principle enable a prediction of the 
solubilizing properties of mixtures of βCD or γCD, assuming that no other equilibria are present. 
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This will be explored in the following where the solubilizing properties of the mixtures are 
presented and discussed. 
 
Additive effects in region I 
In region I there is no precipitation of complexes, and the precipitate consists exclusively of solid 
DX. This definition was used to determine which of the mixed samples belonged to region I. The 
gravimetric analysis of the precipitate could clearly distinguish between samples with and without 
precipitated complexes. The concentration of dissolved DX is shown in Figure 4A as a function of 
the total amount of added β and γCD. The CDs were mixed in various ratios with concentrations 
ranging from 0-25 mM for βCD and 0-13 mM for γCD. These ranges extend slightly into region II 
of the individual PS diagrams. 
 
Figure 4 A) The total concentration of DX as a function of the total concentration of βCD and γCD. The color code indicates the ratio 
of γCD to βCD, ranging from dark blue for 100% βCD to red for 100% γCD. B) Measured DX concentration vs predicted concentration. 
The slope of the regression line indicates excellent agreement between measured and predicted concentration of DX in the presence 




As seen on Figure 4A the concentration of DX increases linearly up to a total CD concentration of 
around 35 mM. At this point, the DX concentration reaches 18 mM which is more than twice as 
high as in the experiments with the individual CDs. There is some scatter on the plot which is 
expected as the DX solubility is not unequivocally given by the total CD concentration but depends 
on the relative amounts of βCD or γCD. Since γCD is a more efficient solubilizer than βCD, 
samples with a higher ratio of γCD to βCD can solubilize more DX, even if the total CD 
concentration is the same. 
If the presence of two different kinds of CDs does not result in any new species, such as new types 
of complexes or aggregates, the total concentration of solubilized DX should be equal to the sum of 
free DX and DX complexed with βCD and γCD: 
𝐷𝐷𝑋𝑋𝑒𝑒𝑒𝑒 = [𝐷𝐷𝑋𝑋] + [𝛽𝛽𝛽𝛽𝐷𝐷:𝐷𝐷𝑋𝑋] + [𝛾𝛾𝛽𝛽𝐷𝐷:𝐷𝐷𝑋𝑋]   (10) 
This can be expressed as: 






𝛾𝛾𝛽𝛽𝐷𝐷𝑡𝑡   (11) 
where Kβ and Kγ are the 1:1 binding constants, and βCDt and γCDt are the amounts of added CDs, 
expressed as concentrations. There was a small difference between the binding constants 
determined by ITC and those determined from region I of the individual PS diagrams. Insertion of 
the latter into eq. 11 yields an excellent agreement between the observed and predicted 
concentrations, as shown in Figure 4B. Using the ITC values, the predicted concentrations become 
around 8% larger than the measured concentrations. The excellent agreement between observations 





Phase-solubility diagram with constant amount of γCD and varied amount of βCD 
To investigate the combined effects of β and γCD in the other regions of the PS diagram, DX was 
dissolved in a series of CD mixtures containing a fixed amount of γCD (20 mM) and varied 
concentrations of βCD. The 20 mM of γCD was chosen well beyond the transition from region I to 
region II in order to avoid super-saturation which tends to occur close to the transition point (see 
Figures 2 and 3). All samples were therefore expected to contain precipitated 3:2 γCD:DX 
complexes and were thus in region II or III with respect to γCD. With respect to βCD, the samples 
ranged from region I, at low concentrations of βCD, to region IIA at high concentrations of βCD, as 
seen in Figure 5. βCD at low concentrations solubilizes DX as a 1:1 complex and then precipitate as 
a 2:1 complex once the solubility product, 𝐾𝐾𝑆𝑆21, is reached (region II). Additional amounts of βCD 
depletes the solid DX, leading to a decrease in the amount of dissolved DX (region III). The 
decrease in region III is not as steep as in the PS diagrams of the individual CDs, since the 
precipitation of DX as solid βCD complexes is partially countered by dissolution of solid γCD 
complexes. Once the concentration of free βCD exceeds the intrinsic solubility of βCD the plateau 




Figure 5 Solubility of DX in samples containing 20.34 mM γCD and varied amounts of βCD. Symbols denote experimental 
measurements. Solid lines are model predictions, using the same parameters as for the modelling of the PS diagrams with individual 
CDs. Details of the modelling are provided as Supporting Information. The total concentration of dissolved CD (red symbols and 
lines, right axis) is given in mg/ml as the gravimetric method determines the total mass of CD, and this cannot be converted to 
number of moles without knowing the relative amounts of the two CDs. 40 mM DX was added to most samples but the round 
symbols came from samples where 21 mM DX was added. Increased amounts of added DX should only result in a linear shift along 
the x-axis, and the round symbols where shifted accordingly along the x-axis.  
 
The measured concentrations of DX and CD are shown in Figure 5 along with the model 
predictions. The overall shape of the PS diagram, including the transitions between the regions, is in 
reasonable agreement with the model predictions, based on additive effects of β and γCD. As 
expressed in eq. 10, additivity implies that the total DX concentration is the sum of free DX and that 
present as 1:1 complexes with β and γCD. Although the overall shape seems correct, the DX 
solubilities and the concentrations of dissolved CD exceeds the predictions. This tendency is hardly 
seen in region I, but it seems clear in region II and is very pronounced in region IIA where the DX 
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concentration is almost twice as high as predicted. Region II and region IIA are discussed in the 
following. 
 
Weak synergistic effect in region II 
In region II, the additive model predicts the height of the plateau to be 15.1 mM but the 
experimental DX concentrations are around 18 mM. This seems to indicate a slight synergistic 
effect. There is a chance, however, that these discrepancies could be due to a slight deviation from 
the temperature at which the parameters were determined. To avoid such errors and get a 
statistically significant answer to whether there is a slight synergistic effect, three new samples were 
made in quadruplicate. The samples contained 40 mM DX and either βCD, γCD, or a mix of the 
two CDs. All samples were processed exactly the same way with respect to temperature, 
equilibration time, and resting time before analysis. In the 4 identical samples containing 40 mM 
DX and 40 mM βCD, the concentration of solubilized DX was 8.19 ± 0.07 mM which is quite close 
to the previously observed plateau value of 7.90 mM (Figure 3). In similar good agreement with 
previous results, the 4 identical samples containing 40 mM DX and 20 mM γCD solubilized 6.79 ± 
0.08 mM DX. The 4 mixed samples containing 40 mM βCD and 20 mM γCD, solubilized 16.84 ± 
0.34 mM DX. This is around 2 mM more than the combined effects of β and γCD, thus confirming 
what seems to be a weak synergistic effect. 
 
Strong synergistic effect in region IIA 
The modelling in Figure 5 shows that two samples are inside region IIA. This region is 
characterized by the presence of pure solid βCD, the presence of which was confirmed by a small 
endothermic peak at 220-225°C in the DSC curves.22 Solid βCD was also identified in the sample 
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right before region IIA (at 70 mM added βCD) but not in any other samples. The attribution of this 
peak to solid βCD is supported by its presence in all of the region IIA samples of the PS diagram 
with βCD where the peak area was roughly proportional to the amount of solid βCD. The additive 
model predicts a DX concentration of 8.9 mM but the measured concentrations were around 15 






The PS diagrams of DX with the individual CDs were well described by equilibrium models in 
which DX forms water-soluble 1:1 complexes with CD and precipitates as higher-order complexes. 
Precipitation takes place when the product of the concentrations exceeds the solubility product of 
the precipitate. For βCD, precipitation occurs when the total concentration of βCD exceeds 17 mM. 
At this point, the concentration of DX is 7.9 mM, and this is the maximum amount of DX that can 
be solubilized by βCD. γCD can solubilize up to 7 mM DX, which requires addition of 10 mM 
γCD. When both CDs are present, the solubilizing effects are additive, and the apparent solubility of 
DX can reach 17 mM. This is because the linearly increasing part of the PS diagram is extended, 
and precipitation does not occur until a total of more than 30 mM CD has been added. Most 
modified CDs, such as partially methylated, sulfobutylated and hydroxypropylated CDs, are 
complex mixtures containing hundreds of CD isomers and homologues. Each of these isomers may 
in principle precipitate with a drug, but as the concentration of each isomer is very low precipitation 
will not occur. This is probably the reason why modified CDs give A-type PS diagrams. Same 
phenomenon contributes to the increased solubility of modified CDs for which the solubility is the 
sum of the independent solubilities of its components.23 The present work shows that this “multiple 
component effect” can be exploited to improve the solubilizing properties of the natural CDs, 
thereby expanding their usage.  
Precipitation of complexes is not a problem that is limited to the natural CDs. All pure CDs may 
suffer from this limitation. For example, two promising neutral βCD thioethers with a strong 
affinity for steroids turned out to be poor solubilizers due to precipitation of complexes.24 Mixtures 
of high-affinity CDs may to some extent alleviate such problems and form a strong-binding 
alternative to the conventional modified CDs. 
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The additive model assumes that the apparent solubility of DX is given as the sum of [DX], 
[βCD:DX] and [γCD:DX] (eq. 10), and that these concentrations in turn are given by the 
complexation constants for the 1:1 complexes and the solubility products of the precipitated entities 
(eq. 6 and 7). In other words, the equilibria that describes the PS diagrams with the individual CDs 
are assumed to describe the solubility of DX when both CDs are present. In region I, when no CDs 
had precipitated, the combined effect of β and γCD was well described by the additive model. In 
contrast, synergistic effects were observed in region II and region IIA of the PS diagram with the 
CD mixtures. This indicates that other equilibria than those described by equations 6 and 7 become 
relevant. We speculate that additional soluble species may form, for instance a 1:1:1 complex 
consisting of one DX molecule binding one βCD and one γCD. Similarly, other solid phases may 
form, such as a solid phase containing DX and both of the CDs. The presence of two CDs opens up 
for the possibility of having several new species in solution and in the precipitate, some of which 
may explain the observed synergistic effects. A proper understanding of these effects may improve 






The BS-type phase-solubility diagrams of DX solubilized by either βCD or γCD were described by 
an equilibrium model in which DX forms water-soluble complexes with a 1:1 stoichiometry and 
precipitates as higher-order complexes, having a stoichiometry of 2:1 βCD:DX or 3:2 γCD:DX. The 
solubility products of the precipitating entities limits the amount of DX in solution to a maximum of 
8 mM and 7 mM, when solubilized by respectively βCD and γCD. The solubilizing properties of 
the CDs are additive, and when DX is solubilized by mixtures of the two CDs the highest 
obtainable concentration increases to 17 mM. The increased solubility is due to the additivity of the 
solubilities of the individual components. This phenomenon also explains why the commonly used 
modified CDs, which are mixtures of hundreds of isomers, give A-type phase-solubility diagrams 
with most drug molecules. 
The phase-solubility diagram of DX with mixtures of βCD or γCD reveals not only additive but 
also significant synergistic effects in some regions of the phase solubility diagram. This suggests 
the presence of additional species in solution, but this explanation is so far purely speculative. 
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